Glivec en es it fr

Glivec Brand names, Glivec Analogs

Glivec Brand Names Mixture

  • No information avaliable

Glivec Chemical_Formula

C29H31N7O

Glivec RX_link

http://www.rxlist.com/cgi/generic3/gleevec.htm

Glivec fda sheet

Glivec FDA

Glivec msds (material safety sheet)

Glivec Synthesis Reference

No information avaliable

Glivec Molecular Weight

493.603 g/mol

Glivec Melting Point

226 oC (mesylate salt)

Glivec H2O Solubility

Very soluble in water at pH < 5.5 (mesylate salt)

Glivec State

Solid

Glivec LogP

3.218

Glivec Dosage Forms

Capsule; Tablet

Glivec Indication

For the treatment of newly diagnosed adult patients with Philadelphia chromosome positive chronic myeloid leukemia (CML). Also indicated for the treatment of pediatric patients with Ph+ chronic phase CML whose disease has recurred after stem cell transplant or who are resistant to interferon-alpha therapy. Also indicated with unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).

Glivec Pharmacology

Imatinib is an antineoplastic agent used to treat chronic myelogenous leukemia. Imatinib is a 2-phenylaminopyrimidine derivative that functions as a specific inhibitor of a number of tyrosine kinase enzymes. In chronic myelogenous leukemia, the Philadelphia chromosome leads to a fusion protein of Abl with Bcr (breakpoint cluster region), termed Bcr-Abl. As this is now a continuously active tyrosine kinase, Imatinib is used to decrease Bcr-Abl activity.

Glivec Absorption

Imatinib is well absorbed with mean absolute bioavailability is 98% with maximum levels achieved within 2-4 hours of dosing

Glivec side effects and Toxicity

Side effects include nausea, vomiting, diarrhea, loss of appetite, dry skin, hair loss, swelling (especially in the legs or around the eyes) and muscle cramps

Glivec Patient Information

Glivec Organisms Affected

Humans and other mammals